Appointment of Director

RNS Number : 7319B

Advanced Oncotherapy PLC

08 April 2013

 



ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

APPOINTMENT OF DIRECTOR

Advanced Oncotherapy (AVO) is pleased to announce the appointment of Tim Lebus as a Non-Executive director of the Company.

Timothy Andrew Lebus is a Senior Adviser at Duke Street. Mr. Lebus has over 30 years experience in private equity and mergers & acquisitions. Prior to joining Duke Street as a partner in 2001, Mr. Lebus was a Managing Director in the Financial Sponsor coverage group at Deutsche Bank AG. He was an Investment Banker for over 20 years at Deutsche Bank, Charterhouse Bank and Salomon Brothers and has extensive experience of working with private equity firms. He previously practised as a Barrister in London and as a Corporate Lawyer in New York. Mr. Lebus is a Non-Executive Director of Bibby Line Group and Octopus Titan VCT 3 Plc. He also serves on behalf of Octopus Ventures as board observer to GetLenses Group Ltd and Executive Channel Europe Limited. Mr. Lebus previously served on the Boards of a number of Duke Street investee companies including Simple Health & Beauty Limited and Affinity Healthcare Limited. He was also on the Business Development Board of SCOPE. He holds a degree in Law from Magdalene College, Cambridge.

Current Directorships	Past Directorships
Bibby Line Group Limited	Duke Street Capital General Partner Limited
Octopus Titan 3 VCT Limited	Duke Street Capital III Limited
	Duke Street Capital V Limited
	Focus DIY Group Limited
	OFS (DS) Acquisitions Limited
	OFS (DS) Finance Limited
	Biwater Holdings Limited

There is no further information required to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules.

Commenting on the appointment, Michael Sinclair, Chief Executive said "Tim's broad investment banking experience and his knowledge of private equity and venture capital adds a dynamic expertise that is crucial to our established board of directors."

Lord David Evans, chairman of AVO, said that he is delighted to welcome Tim Lebus, who will bring a wealth of valuable experience to the board.

For further information, please contact:

Michael Sinclair, Chief Executive	Sandy Jamieson	Jon Levinson	Simon Hudson,
Advanced Oncotherapy Group Plc	Libertas Capital Corporate Finance Ltd	Peterhouse Corporate Finance	Tavistock Communications
0203 617 8739	(NOMAD & Joint Broker)	(Joint Broker)	(Financial PR & IR)
	020 7569 9650	020 7469 0930	020 7920 3150

About Advanced Oncotherapy

Advanced Oncotherapy is a provider of new technology for innovative and patient-focused cancer treatments. These are technologies endorsed internationally by UK and global cancer clinicians, but not currently available in the NHS nor the private sector. Such initiatives build on the Group's 28.75% stake in Advanced Proton Solutions (Holdings) Ltd and its Oncotherapy Resources business focused on non-melanoma skin cancer and early stage breast cancer. Advanced Proton Solutions is pioneering the use of Proton Beam Therapy in the UK. They have secured planning approval for its first proton beam therapy center in the UK in the City of London. In 2011, over 70,000 patients were treated worldwide with proton beam therapy in 32 centres.

-ends-

 

END

 

 

BOASSWFIIFDSEEL